GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to wipe out stomach cancer before surgery
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy and trastuzumab can improve outcomes for people with HER2-positive stomach or gastroesophageal junction cancer that can be surgically removed. About 42 participants will receive treatment…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 11:52 UTC
-
New hope for stomach cancer patients: targeted drug shows promise in Late-Stage trial
Disease control OngoingThis study tests a new drug, trastuzumab deruxtecan, against a standard combination therapy in people with advanced HER2-positive stomach or gastro-esophageal junction cancer that has worsened after initial treatment. About 490 adults will be randomly assigned to receive either t…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 26, 2026 11:49 UTC
-
Heated chemo wash during surgery may stop stomach cancer spread
Disease control ENROLLING_BY_INVITATIONThis study tests whether giving heated chemotherapy directly into the abdomen during surgery can prevent stomach or gastroesophageal cancer from coming back in the belly lining. It is for 16 adults with high-risk cancer. The approach aims to kill any stray tumor cells that might …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 11:48 UTC
-
New drug trial offers hope for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called TORL-2-307-ADC in people with advanced solid tumors, including stomach, pancreas, and esophageal cancers. The main goals are to find a safe dose and check for side effects. About 163 participants will receive the drug to see if it ca…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
New hope for stomach cancer: targeted drug combo enters late-stage trial
Disease control OngoingThis study tests whether adding the drug bemarituzumab to standard chemotherapy and immunotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial includes about 515 adults whose tumors have a specific protein called FGFR2b. The goal i…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for stomach cancer: triple therapy targets tough tumors
Disease control OngoingThis study tests a new drug called ASKB589 added to standard chemotherapy and immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). The goal is to see if the combination helps keep the cancer from growing longer …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New drug combo shows promise in fighting esophageal cancer
Disease control OngoingThis study tests the safety of adding the drug durvalumab to standard chemoradiation for people with esophageal or gastroesophageal junction cancer. About 64 participants will receive initial chemotherapy followed by chemoradiation plus durvalumab. The goal is to see if this comb…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New chemo combo targets stomach cancer in the belly
Disease control OngoingThis study tests a treatment for stomach cancer that has spread to the lining of the abdomen. It combines standard chemotherapy given through a vein with chemotherapy delivered directly into the belly. The goal is to see if this approach helps control the cancer and improves surv…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Immunotherapy combo shows promise in esophageal cancer fight
Disease control TerminatedThis study tests whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer. About 278 adults with stage II to IVA cancer will receive the combination before and after s…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New hope for tough cancers: SKB264 trial targets tumors resistant to standard care
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not improved with standard treatments. The goal is to find the best dose and see if it can shrink tumors. About 1,410 participants will receive the drug…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New hope for stomach cancer: immunotherapy combo shows promise in genetic subtype
Disease control OngoingThis study tests whether the immunotherapy drug atezolizumab, alone or with chemotherapy, can shrink or control a specific type of stomach or gastroesophageal junction cancer that has a high number of genetic mutations (MSI-H/dMMR). About 240 adults with early-stage but resectabl…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New drug cocktail aims to shrink HER2+ stomach tumors before surgery
Disease control OngoingThis study tests whether a combination of targeted drugs (trastuzumab deruxtecan, capecitabine, and durvalumab) can shrink HER2-positive stomach or gastroesophageal junction cancer before surgery and prevent return after surgery. About 64 adults with untreated, advanced but not s…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug combo shows promise for Tough-to-Treat stomach cancer
Disease control OngoingThis study tests whether adding the drug bemarituzumab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial includes about 547 adults whose tumors have high levels of a protein called FGFR2b. Participants receive e…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 23, 2026 12:45 UTC
-
Virtual diet coaching aims to boost recovery after stomach cancer surgery
Symptom relief OngoingThis study tests whether a telehealth program that provides diet support can help improve nutrition and quality of life for people who have had surgery for stomach or esophagus cancer. About 53 adults who recently started eating again after surgery will take part in online sessio…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated May 20, 2026 11:57 UTC